Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. - Wikidata - awgldk - TriplyDB

Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program.

Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program.

http://www.wikidata.org/entity/Q30496787

about

The bigger picture of FTO: the first GWAS-identified obesity gene NIH working group report-using genomic information to guide weight management: From universal to precision treatment HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.Lifestyle and precision diabetes medicine: will genomics help optimise the prediction, prevention and treatment of type 2 diabetes through lifestyle therapy?FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials.Putting the Genome in Context: Gene-Environment Interactions in Type 2 Diabetes.Gene × dietary pattern interactions in obesity: analysis of up to 68 317 adults of European ancestry.Obesity susceptibility loci and dietary intake in the Look AHEAD Trial.FTO predicts weight regain in the Look AHEAD clinical trial Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials.FTO variant rs9939609 is associated with body mass index and waist circumference, but not with energy intake or physical activity in European- and African-American youth Recent progress in the genetics of common obesity Invited commentary: Gene X lifestyle interactions and complex disease traits--inferring cause and effect from observational data, sine qua non.Common INSIG2 polymorphisms are associated with age-related changes in body size and high-density lipoprotein cholesterol from young adulthood to middle age.Common genetic variants and central adiposity among Asian-Indians.The genetics of obesity: FTO leads the way.Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children.Life-course analysis of a fat mass and obesity-associated (FTO) gene variant and body mass index in the Northern Finland Birth Cohort 1966 using structural equation modeling.Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.TFAP2B influences the effect of dietary fat on weight loss under energy restriction.Prospective analysis of the association of a common variant of FTO (rs9939609) with adiposity in children: results of the IDEFICS study.Human cardiovascular disease IBC chip-wide association with weight loss and weight regain in the look AHEAD trial.Gene × physical activity interactions in obesity: combined analysis of 111,421 individuals of European ancestry.Inherited destiny? Genetics and gestational diabetes mellitus.Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Associations between FTO genotype and total energy and macronutrient intake in adults: a systematic review and meta-analysis.Physical activity, smoking, and genetic predisposition to obesity in people from Pakistan: the PROMIS study.The new perspectives on genetic studies of type 2 diabetes and thyroid diseases Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects Do genetic variations alter the effects of exercise training on cardiovascular disease and can we identify the candidate variants now or in the future?Gene × environment interactions in type 2 diabetes.Impact of variation near MC4R on whole-body fat distribution, liver fat, and weight loss.Evaluation of weight loss and adipocytokines levels after two hypocaloric diets with different macronutrient distribution in obese subjects with rs9939609 gene variant.Effects of RS9939609 gene variant in FTO gene on weight loss and cardiovascular risk factors after biliopancreatic diversion surgery.Effects of FTO genotype on weight loss and metabolic risk factors in response to calorie restriction among Japanese women.Associations of markers in 11 obesity candidate genes with maximal weight loss and weight regain in the SOS bariatric surgery cases.Relationship between MTNR1B (melatonin receptor 1B gene) polymorphism rs10830963 and glucose levels in overweight children and adolescents.

P2860

Q24562954-7CB157B9-7D60-48DA-B1D6-EA33D3048968 Q26773982-FD213AC2-C1AE-45D0-BD6B-CF36F6CEB5E7 Q27335063-A4DC6867-1990-4EFB-84AB-A3590B1A387B Q30238781-9A9A8600-1A56-4798-8A02-F1ED643096C3 Q30245187-32C22024-8AB1-448A-AB1A-E47ADEDB835B Q30251394-C34C1F7A-5F7A-43B5-BA76-D8B62EF1E57E Q30299908-B7577C4C-9B4E-4CD6-89EE-B1198E404E09 Q30514020-7F2CAA2B-37B9-4C7D-B9CD-53DE29B11DE7 Q30543330-58038388-FD6D-4289-B6EB-F698CC60070C Q30681813-40E8A9D0-AA17-4A88-82DD-49AAB3BA5043 Q33551072-C77C4931-3590-4FC2-BB7F-144EB6DB4547 Q33607966-66DE7199-DB1B-4C88-B34A-8823FD8C7CBE Q33694207-36ADAD95-EDE0-425D-8C31-1BA65F768959 Q33925838-D3F630F0-486E-48B8-8F00-352AAE63334A Q33974823-4DC8621C-CEB9-404D-9960-37189DF7BAFF Q34005975-253B9920-BC6B-419D-AF4D-9243AB23EC40 Q34070466-C7FF78AD-6B7B-44FF-8372-21A9E9318650 Q34122862-ED559A91-3716-4F39-AB66-40E5E6DCF9CA Q34294192-67A835C8-F105-4CA1-87F8-7CBB1021DDBC Q34405011-0F5CEC20-BE54-4A80-9B2D-03032963DF35 Q34479155-A203B0C2-1C38-4B8E-A819-31017D348F8E Q34641723-BFBD3E2E-3522-40FE-BF43-EC407E2E5587 Q34916970-F93EAC9D-8A4B-4BD2-8814-AF18FB65675A Q34971477-447CCE8C-8BA6-4BAB-AB66-4EBFBDFCB325 Q35039274-8DEED257-D92B-4466-AE60-2265F97F49E2 Q35643115-416A02EA-BC91-4604-924F-4E525F77F92B Q35873193-272139D6-A860-46AA-B110-D617DEC95906 Q36634117-53945AE9-D932-4007-AAA4-30239A9AE415 Q36782845-2BFCABC4-4D23-4CEF-B817-090EBF2C5941 Q37874857-E9EFB29F-AEE4-4D94-8549-0FFDA5BDB551 Q37925665-6FDF1F78-67EC-4EA1-8D95-F14AF232E880 Q45921270-385BDDE3-73A4-4E07-96E3-94B26FA529B5 Q47293333-134F2112-69F4-40BF-911A-99AA49E8A4F0 Q47327665-0028589C-6962-4971-9E90-B9EBC536D02E Q47348539-5E7501B3-873D-4179-9E8F-5D4BC61CDFD5 Q47418018-9ACE90E3-ED38-42A7-BFCF-9B122A579116 Q51377986-4702379D-F08B-46CC-8957-2A50A4CE66FC

P2860

Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program.

http://www.wikidata.org/entity/Q30496787

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Assessing gene-treatment inter ...... e Diabetes Prevention Program.

@ast

Assessing gene-treatment inter ...... e Diabetes Prevention Program.

@en

type

label

Assessing gene-treatment inter ...... e Diabetes Prevention Program.

@ast

Assessing gene-treatment inter ...... e Diabetes Prevention Program.

@en

prefLabel

Assessing gene-treatment inter ...... e Diabetes Prevention Program.

@ast

Assessing gene-treatment inter ...... e Diabetes Prevention Program.

@en

P1433

Q30496787-195BB62F-2257-46CC-82AD-91D8300BCE11

P1476

Q30496787-3DB29106-D9B4-4DA4-A2DF-E8716C2A18B4

P2093

Q30496787-1B73BA36-408F-4ECC-AB3F-D4E1FAEED604

Q30496787-6ED18737-BC69-4485-AF07-D1318DA1FD51

Q30496787-78D91171-000C-4180-9B54-0A35502F660A

Q30496787-916EC24C-BCC5-455D-84F6-6E2BF5611B47

Q30496787-ADFDE785-597D-401F-A061-9477BC12816A

P2860

Q30496787-026A9218-168E-43B8-85E1-FAD33E9D56C0

Q30496787-07C984D5-DC33-4CBE-AFF3-CF86FEFC3FE3

Q30496787-0D142B43-2BCE-48D1-B469-2C45410040B4

Q30496787-0EF1DCDA-BADC-4D2D-BDB0-DADAA880B77F

Q30496787-1727C0ED-EF72-40E6-85D2-808016C18E34

Q30496787-1817D143-5396-42B4-AA7D-A9E9948605F1

Q30496787-19873B83-3394-4308-BB54-19DD701F3827

Q30496787-24948D5E-48B1-402D-B2F0-DF6D81909775

Q30496787-4A1BF00C-705A-4B5F-A76E-8813B9C57F4A

Q30496787-53A0792D-54A2-4528-987C-FB192C515F7E

P2888

Q30496787-FF90EA55-7158-406F-8BEB-1E3BFC5C4AB6

P304

Q30496787-8DD725F6-1878-49EF-B8AD-C0EC68E3EA63

P31

Q30496787-71B1B046-A1E2-441B-972F-B786DAC82AE5

P356

Q30496787-BF3CD55A-1441-4969-A37F-24F12260FACA

P433

Q30496787-ED0A7107-5D5B-4A45-91FD-E890A1E68F75

P478

Q30496787-AEE46469-6AC1-4DC0-AC49-88D000F3574F

P50

Q30496787-53358928-DBAB-4AA6-99B4-742190D12778

Q30496787-C507A827-A0FE-418D-B61D-C7B223914DAA

Q30496787-EC7B50FE-EBB7-4FE0-B42B-C169308F1381

P577

Q30496787-FF1C835F-3A4C-4DB9-B14D-1C224C622E5A

P5875

Q30496787-57E72706-7FB0-4D51-953B-FAA525B0B2AF

P6179

Q30496787-F368E3CD-B621-4227-A309-3F87896EE0BD

P698

Q30496787-5E01A94B-B6B6-43E8-8245-0CAE2180FD42

P921

Q30496787-6D5A7D74-CC4B-49F5-8DE2-24179314C7CE

P932

Q30496787-4CB9F100-6073-42CB-9576-18862A8D6B4D

P356

S00125-008-1158-X

P1433

P1476

Assessing gene-treatment inter ...... e Diabetes Prevention Program.

@en

P2093

J B McAteer

http://www.w3.org/2001/XMLSchema#string

J C Florez

http://www.w3.org/2001/XMLSchema#string

K A Jablonski

http://www.w3.org/2001/XMLSchema#string

L M Delahanty

http://www.w3.org/2001/XMLSchema#string

W C Knowler

http://www.w3.org/2001/XMLSchema#string

P2860

The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase

Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins

A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity

The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain

Association of morbid obesity with FTO and INSIG2 allelic variants

Variation in FTO contributes to childhood obesity and severe adult obesity

A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.

P2888

s00125-008-1158-x

P304

2214-2223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-008-1158-X

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Diabetes Prevention Program Research Group

P577

2008-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

226360140

http://www.w3.org/2001/XMLSchema#string

P6179

1019597783

http://www.w3.org/2001/XMLSchema#string

P698

18839134

http://www.w3.org/2001/XMLSchema#string

P921

P932

2947367

http://www.w3.org/2001/XMLSchema#string